Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Exchange Rate Effect (2020 - 2025)

Cytek Biosciences' Exchange Rate Effect history spans 6 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Exchange Rate Effect fell 6.98% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $109000.0, down 97.59%, while the annual FY2025 figure was $109000.0, 97.59% down from the prior year.
  • Exchange Rate Effect reached $1.4 million in Q4 2025 per CTKB's latest filing, up from $846000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $2.3 million in Q2 2024 to a low of -$1.4 million in Q2 2022.
  • Average Exchange Rate Effect over 5 years is $100400.0, with a median of $61000.0 recorded in 2021.
  • The largest YoY upside for Exchange Rate Effect was 2233.33% in 2022 against a maximum downside of 1034.0% in 2022.
  • A 5-year view of Exchange Rate Effect shows it stood at $678000.0 in 2021, then crashed by 247.79% to -$1.0 million in 2022, then grew by 17.86% to -$823000.0 in 2023, then surged by 284.45% to $1.5 million in 2024, then dropped by 6.98% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Exchange Rate Effect are $1.4 million (Q4 2025), $846000.0 (Q3 2025), and -$921000.0 (Q2 2025).